Concepts (75)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 7 | 2022 | 33 | 3.350 |
Why?
|
| Prostatic Neoplasms | 5 | 2021 | 778 | 2.170 |
Why?
|
| Androgen Antagonists | 2 | 2022 | 45 | 0.960 |
Why?
|
| Androstenes | 2 | 2019 | 6 | 0.800 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 28 | 0.620 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 95 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 468 | 0.580 |
Why?
|
| Radiopharmaceuticals | 3 | 2022 | 114 | 0.560 |
Why?
|
| Transcriptome | 1 | 2018 | 164 | 0.550 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2014 | 116 | 0.550 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 306 | 0.520 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 931 | 0.520 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 508 | 0.510 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2014 | 21 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 446 | 0.400 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2022 | 41 | 0.390 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 7 | 0.370 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 30 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 151 | 0.320 |
Why?
|
| Male | 13 | 2022 | 37321 | 0.310 |
Why?
|
| Humans | 14 | 2022 | 68618 | 0.230 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2022 | 17 | 0.210 |
Why?
|
| Androgens | 1 | 2022 | 41 | 0.210 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 31 | 0.190 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 138 | 0.190 |
Why?
|
| Pyrimidinones | 1 | 2021 | 26 | 0.190 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 58 | 0.190 |
Why?
|
| Platinum | 1 | 2020 | 17 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 84 | 0.190 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2020 | 6 | 0.180 |
Why?
|
| Anilides | 1 | 2019 | 16 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 170 | 0.160 |
Why?
|
| Radiotherapy | 1 | 2019 | 86 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 110 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 334 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2020 | 215 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2019 | 110 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 206 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2019 | 111 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 87 | 0.150 |
Why?
|
| Pyridines | 1 | 2019 | 261 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 186 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2022 | 7277 | 0.140 |
Why?
|
| Prognosis | 2 | 2019 | 2093 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 511 | 0.130 |
Why?
|
| Cytogenetic Analysis | 1 | 2014 | 12 | 0.120 |
Why?
|
| Tandem Repeat Sequences | 1 | 2014 | 13 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 86 | 0.120 |
Why?
|
| Azacitidine | 1 | 2014 | 20 | 0.120 |
Why?
|
| DNA Repair | 1 | 2014 | 127 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 77 | 0.110 |
Why?
|
| Mutation | 1 | 2019 | 1213 | 0.110 |
Why?
|
| Aged | 6 | 2020 | 14862 | 0.110 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 499 | 0.100 |
Why?
|
| Middle Aged | 6 | 2020 | 21147 | 0.090 |
Why?
|
| Female | 6 | 2020 | 38074 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4848 | 0.060 |
Why?
|
| Everolimus | 1 | 2022 | 26 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 34 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 78 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2022 | 140 | 0.050 |
Why?
|
| Cisplatin | 1 | 2022 | 192 | 0.050 |
Why?
|
| Adult | 2 | 2020 | 21403 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 27 | 0.040 |
Why?
|
| Arthritis | 1 | 2018 | 53 | 0.040 |
Why?
|
| Pneumonia | 1 | 2018 | 110 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 536 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 714 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2022 | 7029 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 848 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 3705 | 0.030 |
Why?
|
| Remission Induction | 1 | 2014 | 111 | 0.030 |
Why?
|
| Neoplasms | 1 | 2018 | 1667 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 4655 | 0.020 |
Why?
|